Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: Transcriptomic Analysis of Contralateral Healthy Mucosa in Oropharyngeal Squamous Cell Carcinoma (OPSCC) Patients

PROVIDER: PRJNA1069986 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR27753390.fastq.gz	Fastqsanger.gz
	SRR27753391.fastq.gz	Fastqsanger.gz
	SRR27753392.fastq.gz	Fastqsanger.gz
	SRR27753393.fastq.gz	Fastqsanger.gz
	SRR27753394.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 6

Similar Datasets

DNA methylation analysis in oropharyngeal cancer [450K array]

Project description:DNA methylation analysis in oropharyngeal squamous carcinoma (OPSCC) samples and oropharyngeal non-cancerous mucosa samples. Infinium HumanMethylation450 BeadChip was used to obtain DNA methylation profiles across 485,577 CpG sites. Total samples included 89 OPSCC samples and 5 non-cancerous mucosa samples.

2020-01-20 | GSE124464 | GEO

DNA methylation analysis in oropharyngeal cancer [EPIC array]

Project description:DNA methylation analysis in oropharyngeal squamous carcinoma (OPSCC) samples and oropharyngeal non-cancerous mucosa samples. Infinium MethylationEPIC BeadChip Kit was used to obtain DNA methylation profiles across more than 850,000 CpG sites. Total samples included 89 OPSCC samples and 5 non-cancerous mucosa samples.

2020-01-20 | GSE124632 | GEO

DNA methylation analysis in head and neck cancer cells

Project description:DNA methylation analysis in oropharyngeal squamous carcinoma(OPSCC) samples, oropharyngeal non-cancerous mucosa samples and head and neck cancer cell lines, FaDu and UMSCC47 before and after 5-aza'2-deoxycytidine(Aza)/trichostatin A(TSA) treatment. Infinium HumanMethylation450 BeadChip was used to obtain DNA methylation profiles across 485,577 CpG sites. Samples included 13 OPSCC samples, 4 non-cancerous mucosa samples and 2 FaDu with and without Aza/TSA treatment and 2 UMSCC47 with and without Aza/TSA treatment.

2018-05-10 | GSE98807 | GEO

Next generation sequencing facilities quantitative analysis of human oropharyngeal squamous cell carcinoma, small cell carcinoma and non-cancerous tonsil tissue.

Project description:To investigate the differences of transcriptional activities between oropharyngeal squamous cell caricnoma and small cell carcinoma, we performed a transcriptomic analysis using high throoughput RNA sequencing (RNA-seq).

2021-02-16 | GSE166773 | GEO

Transcriptomic Profiling of Oropharyngeal Squamous Cell Carcinoma

Project description:Transcriptomic Profiling of Oropharyngeal Squamous Cell Carcinoma

| PRJNA842485 | ENA

Transcriptomic Profiling of Oropharyngeal Squamous Cell Carcinoma

Project description:Transcriptomic Profiling of Oropharyngeal Squamous Cell Carcinoma

| PRJNA842484 | ENA

Expression Profiling of Oral Squamous Cell Carcinoma and Mucosa of healthy non-tumor patients

Project description:In an attempt to further elucidate the pathomechanisms in oral squamous cell carcinoma (OSCC), gene expression profiling to a set of 35 primary OSCCs compared to 6 oral mucosa from healthy non-tumor patients was performed. Keywords: expression profiling Gene expression profiling using a whole-transcriptome chip that contains 35,035 gene-specific 70mere oligonucleotides (Human Oligoset 4.0; Operon) to a set of 35 primary OSCCs and 6 mucosa of healthy non-tumor patients.

2008-01-12 | E-GEOD-10121 | biostudies-arrayexpress

Expression Profiling of Oral Squamous Cell Carcinoma and Mucosa of healthy non-tumor patients

2008-01-12 | GSE10121 | GEO

DNA methylation analysis of oropharyngeal squamous cell carcinoma

Project description:DNA methylation analysis of oropharyngeal squamous cell carcinoma

| PRJNA737789 | ENA

A proteomic signature for human papillomavirus-associated oropharyngeal squamous cell carcinoma predicts patients at high risk of recurrence

Project description:The incidence of human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC) is increasing and effective treatment for targeting the subset of patients at high risk for recurrence remains a significant clinical challenge. In this study, pre-treatment tumour biopsies were used for proteomic analysis by data-independent acquisition mass spectrometry (DIA-MS) to identify protein and peptide biomarker signatures able to stratify patients at low, intermediate, or high-risk of recurrence. For further details, refer to the publication that accompanies this data deposition.

2025-02-23 | PXD036891 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data